HDAC11 and metabolic dysfunction-associated steatotic liver disease: Given that B6 was identified as a potent selective inhibitor of HDAC11, we assessed its efficacy in the in vitro models of MASLD established with both HepG2 (Figure S3, Supporting Information) and AML12 cells (Figure5).